Telix Pharmaceuticals Ltd (ASX: TLX) shares got smashed on Monday, plunging 12% to $15.76 after a blockbuster merger announcement. Zoom out, though, and the nuclear healthcare stock is still up 40% year to date — though that gain has shrunk to just 12% over 12 months.
So did the market overreact, or is this the start of something worse?
Image source: Getty Images
The deal
Here's the short version: Telix just agreed to buy Germany's ITM, one of the biggest players in radioisotope production, for US$1.65 billion.
And Telix isn't paying with cash. It's paying with shares – 105.8 million of them, worth about US$1.25 billion. On top of that, it's taking on US$302 million of ITM's debt, plus another US$96 million in transaction costs and management payouts.
That's not all. Telix could end up paying a further US$700 million down the track. That will depend on how ITM's cancer drug ITM-11 performs — up to US$250 million if it clears FDA approval across three indications, and up to US$450 million if sales blow past US$150 million by 2030.
Once the dust settles, current Telix shareholders will own about 76% of the combined company. ITM's shareholders will get the other 24%.
Why the market panicked
In plain terms: Telix just diluted itself, big time. Issuing 105.8 million new Telix shares is a serious jump in shares on issue, and that's really what was crushing the price on Monday. Not doubts about the strategy itself.
The deal still needs shareholder approval at a meeting expected in November, which adds a layer of 'wait and see'. And the combined company's 2026 revenue guidance of just over US$1.3 billion isn't exactly blowing anyone away relative to the price tag. So investors are left weighing genuine strategic upside against real, near-term dilution.
CEO Christian Behrenbruch made the case for why it's worth it:
ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector.
What do brokers think?
Brokers, for the most part, aren't panicking. Five of the latest broker ratings are a buy — Canaccord Genuity, Citi, JPMorgan, UBS and Jarden, while RBC Capital is the lone hold.
Where they disagree is on price. Targets range from $19 all the way to $31, suggesting upsides between 21% and 97%. Canaccord just lifted its target to $30.25, Citi sits at $31 and JPMorgan is at $25.58. Jarden nudged up to $21, while UBS trimmed its target to $22 but kept its buy rating intact.
Foolish takeaway
Every one of those price targets sits well above where Telix shares trade today. Brokers clearly like the story, but they just can't agree on the price tag.
The real test isn't whether the ITM deal makes strategic sense. It probably does. It's whether Telix can actually integrate a US$1.65 billion acquisition, hit ITM-11's regulatory milestones, and prove the dilution was worth it.
Until then, this drop looks more like nerves than a verdict.
